Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.70 |
| ▸ | CTSL | P07711 | 6/20 | 0.68 |
| ▸ | CTSB | P07858 | 5/20 | 0.68 |
| ▸ | CTSS | P25774 | 2/20 | 0.68 |
| ▸ | CTSK | P43235 | 1/20 | 0.68 |
| ▸ | TYR | P14679 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15080871 | 0.94 | TACR1 (0.68) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL29480462 | 0.92 | CTSL (0.66) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL9545976 | 0.92 | CTSL (0.69) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL10049956 | 0.91 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL30241933 | 0.91 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL8100557 | 0.91 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL16095807 | 0.91 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL12052836 | 0.91 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL30688477 | 0.91 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL10722852 | 0.91 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253775-B1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20170283462-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-05 | — | — | US | disclosed |
| US-20160222060-A1 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2016-08-04 | — | — | US | disclosed |
| EP-0883629-A1 | OLIGOPEPTIDES FOR DRUG DELIVERY | Emisphere Technologies, Inc. (US) | 1998-12-16 | — | — | EP | disclosed |
| WO-1997031938-A9 | OLIGOPEPTIDES FOR DRUG DELIVERY | — | 1997-11-20 | — | — | WO | disclosed |
| WO-1997031938-A1 | OLIGOPEPTIDES FOR DRUG DELIVERY | EMISPHERE TECHNOLOGIES, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283462-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | TACR1 3230/4885CTSL 424/4885CTSB 1950/4885 |
| US-20160222060-A1 | Immunomodulators | CD274, PDCD1, PDCD1LG2 | TACR1 3230/4885CTSL 424/4885CTSB 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.